NuVasive receives FDA clearance for expanded indication of synthetic putty
Click Here to Manage Email Alerts
NuVasive Inc. has announced FDA 510(k) clearance for expanded indication of Attrax putty for use in interbody fusion of the thoracolumbar spine, according to a press release.
Attrax putty is a synthetic, biologic and osteoconductive bone void filler, which is designed to perform similar to autograft bone, according to the release.
“The expanded indications of Attrax putty with thoracolumbar implants support the clinical efficacy of Attrax putty and highlight the comparative clinical advantage over competitive biologic offerings in the market,” Ryan Donahoe, chief technology officer at NuVasive, said in the release. “This first and only 510(k) clearance of its kind demonstrates NuVasive's commitment to advancing the standard of spine care – while delivering enhanced economic value to our customers.”
Read more about
Click Here to Manage Email Alerts